Compare RAIL & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAIL | TNXP |
|---|---|---|
| Founded | 1901 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Railroads | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 235.1M | 199.7M |
| IPO Year | 2005 | 2008 |
| Metric | RAIL | TNXP |
|---|---|---|
| Price | $6.17 | $7.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $14.67 | ★ $44.50 |
| AVG Volume (30 Days) | 226.2K | ★ 561.3K |
| Earning Date | 11-09-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 134.94 | 91.75 |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $500,991,000.00 | $13,107,000.00 |
| Revenue This Year | N/A | $319.65 |
| Revenue Next Year | $49.52 | $101.60 |
| P/E Ratio | $19.69 | ★ N/A |
| Revenue Growth | N/A | ★ 29.85 |
| 52 Week Low | $6.24 | $7.42 |
| 52 Week High | $14.90 | $22.38 |
| Indicator | RAIL | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 30.58 | 15.19 |
| Support Level | N/A | N/A |
| Resistance Level | $7.55 | $12.99 |
| Average True Range (ATR) | 0.27 | 0.55 |
| MACD | -0.09 | -0.30 |
| Stochastic Oscillator | 5.91 | 0.95 |
FreightCar America Inc is a diversified manufacturer and supplier of railcars and railcar components. It designs and manufactures a variety of railcar types for transportation of bulk commodities and containerized freight products in North America. The company also provides railcar rebody and repair services, railcar conversion services, and supplies railcar parts. The company has two segments: Manufacturing and Aftermarket. The majority of the company's revenue is derived from the Manufacturing segment, which includes new railcar manufacturing, used railcar sales, and various conversions and rebodies. Geographically, it generates the maximum revenue from the United States.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.